Results 241 to 250 of about 107,669 (285)
Some of the next articles are maybe not open access.
Drugs, 2005
Tuberculosis continues to be a major cause of disease and death throughout the developing world. Chemotherapy is the current method of control but with the continuing emergence of drug resistance, coupled with the reticence of major drug companies to invest in drug discovery, the identification of new vaccines to combat tuberculosis is a pressing need.
R, Srivastava, B S, Srivastava
openaire +4 more sources
Tuberculosis continues to be a major cause of disease and death throughout the developing world. Chemotherapy is the current method of control but with the continuing emergence of drug resistance, coupled with the reticence of major drug companies to invest in drug discovery, the identification of new vaccines to combat tuberculosis is a pressing need.
R, Srivastava, B S, Srivastava
openaire +4 more sources
Enfermedades Infecciosas y Microbiología Clínica, 2011
The current tuberculosis (TB) vaccine, bacille Calmette-Guerin (BCG), is a live vaccine used worldwide, as it protects against severe forms of the disease, saving thousands of lives every year, but its efficacy against pulmonary forms of TB, responsible for transmission of the diseases, is variable.
Carlos Martín Montañés +1 more
openaire +2 more sources
The current tuberculosis (TB) vaccine, bacille Calmette-Guerin (BCG), is a live vaccine used worldwide, as it protects against severe forms of the disease, saving thousands of lives every year, but its efficacy against pulmonary forms of TB, responsible for transmission of the diseases, is variable.
Carlos Martín Montañés +1 more
openaire +2 more sources
Vaccination against Tuberculosis
International Archives of Allergy and Immunology, 1995Recent findings in mice have changed our perception of how protective immunity works in tuberculosis and hold promise for the rapid development of new vaccines. For example, we now know: (1) that a single mycobacterial protein antigen can be sufficient to generate powerful protective immunity, provided that it is presented to the immune system in the ...
D B, Lowrie, R E, Tascon, C L, Silva
openaire +2 more sources
Tuberculosis vaccine development
Current Opinion in Pulmonary Medicine, 2002If the end of the 20th century saw the flowering of genomics, the beginning of the 21st century is witnessing an equally rapid blossoming of proteomics. These twin technologies have had a dramatic influence on the study of tuberculosis (TB), and nowhere more so than in the development of new TB vaccines.
T Mark, Doherty, Peter, Andersen
openaire +2 more sources
Vaccination against tuberculosis
Enfermedades infecciosas y microbiologia clinica (English ed.), 2018BCG (Bacille Calmette-Guérin) vaccination is included in the immunization schedule for tuberculosis endemic countries with a global coverage at birth close to 90% worldwide. BCG was attenuated from Mycobacterium bovis almost a century ago, and provides a strong protection against disseminated forms of the disease, though very limited against pulmonary ...
Carlos, Martin +2 more
openaire +2 more sources
Scandinavian Journal of Infectious Diseases, 2001
DNA vaccines have been the subject of intense investigation for the past 10 y, during which time several tuberculosis (TB) DNA vaccines have been shown to confer protective immunity in animal models. So far, proof of principle for priming of immune responses by a naked DNA vaccine (malaria) has been demonstrated in humans, but potency remains a ...
openaire +2 more sources
DNA vaccines have been the subject of intense investigation for the past 10 y, during which time several tuberculosis (TB) DNA vaccines have been shown to confer protective immunity in animal models. So far, proof of principle for priming of immune responses by a naked DNA vaccine (malaria) has been demonstrated in humans, but potency remains a ...
openaire +2 more sources
2005
The present invention relates to a Mycobacterium bovis (M. bovis) BCG mutant comprising a mutation in a putative undecaprenyl phosphokinase gene (upk), whereby said mutation leads to a partial or complete inactivation of said upk-gene. Also provided are pharmaceutical composition comprising said M. bovis BCG mutant.
MAX PLANCK GESELLSCHAFT +3 more
openaire +2 more sources
The present invention relates to a Mycobacterium bovis (M. bovis) BCG mutant comprising a mutation in a putative undecaprenyl phosphokinase gene (upk), whereby said mutation leads to a partial or complete inactivation of said upk-gene. Also provided are pharmaceutical composition comprising said M. bovis BCG mutant.
MAX PLANCK GESELLSCHAFT +3 more
openaire +2 more sources
The Lancet, 2010
New vaccines are urgently needed if we want to reach the goal of substantially reducing the incidence of tuberculosis by 2050. Despite a steady increase in funding over the past decade, there is still a striking financial shortfall for vaccine research and development for tuberculosis.
Kaufmann, S., Hussey, G., Lambert, P.
openaire +3 more sources
New vaccines are urgently needed if we want to reach the goal of substantially reducing the incidence of tuberculosis by 2050. Despite a steady increase in funding over the past decade, there is still a striking financial shortfall for vaccine research and development for tuberculosis.
Kaufmann, S., Hussey, G., Lambert, P.
openaire +3 more sources